Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (481-490 of 523) with videos related to

Pageof 53
Sort By:
Annals of the Rheumatic Diseases|October 28, 2008
Treatment recommendations for psoriatic arthritisC T Ritchlin, A Kavanaugh, D D Gladman, et al.
Acta Dermato-Venereologica|February 11, 2022
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance DataAlice B Gottlieb, Atul Deodhar, Iain B Mcinnes, et al.
The British Journal of Dermatology|February 26, 2016
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasisK A Papp, K Reich, C Paul, et al.
The British Journal of Dermatology|November 29, 2024
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trialAlexa B Kimball, Falk G Bechara, Aysha Badat, et al.
The Journal of Rheumatology|May 2, 2021
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic ArthritisProton Rahman, Christopher T Ritchlin, Philip S Helliwell, et al.
Pain and Therapy|October 17, 2025
Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical TrialsJohn R Ingram, Hideki Fujita, Alice B Gottlieb, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
Dermatology (Basel, Switzerland)|September 19, 2021
International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual MeetingAlison H Kohn, Afsaneh Alavi, April W Armstrong, et al.
Journal of Clinical Pharmacology|September 3, 2004
The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activityNancy G B Agrawal, Catherine Z Matthews, Ralph S Mazenko, et al.
Pageof 53

Showing results (481-490 of 523) with videos related to

Sort By:
Pageof 53
Annals of the Rheumatic Diseases|October 28, 2008
Treatment recommendations for psoriatic arthritisC T Ritchlin, A Kavanaugh, D D Gladman, et al.
Acta Dermato-Venereologica|February 11, 2022
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance DataAlice B Gottlieb, Atul Deodhar, Iain B Mcinnes, et al.
The British Journal of Dermatology|February 26, 2016
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasisK A Papp, K Reich, C Paul, et al.
The British Journal of Dermatology|November 29, 2024
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trialAlexa B Kimball, Falk G Bechara, Aysha Badat, et al.
The Journal of Rheumatology|May 2, 2021
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic ArthritisProton Rahman, Christopher T Ritchlin, Philip S Helliwell, et al.
Pain and Therapy|October 17, 2025
Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical TrialsJohn R Ingram, Hideki Fujita, Alice B Gottlieb, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
Dermatology (Basel, Switzerland)|September 19, 2021
International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual MeetingAlison H Kohn, Afsaneh Alavi, April W Armstrong, et al.
Journal of Clinical Pharmacology|September 3, 2004
The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activityNancy G B Agrawal, Catherine Z Matthews, Ralph S Mazenko, et al.
Pageof 53